- DAXOR CORP has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has suffered a declining pattern earnings per share over the past two years. During the past fiscal year, DAXOR CORP swung to a loss, reporting -$1.69 versus $1.17 in the prior year.
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 165.8% when compared to the same quarter one year ago, falling from $2.27 million to -$1.49 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, DAXOR CORP's return on equity significantly trails that of both the industry average and the S&P 500.
- The share price of DAXOR CORP has not done very well: it is down 5.74% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
- The gross profit margin for DAXOR CORP is currently very high, coming in at 71.27%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -404.33% is in-line with the industry average.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices traded up today with the Dow Jones Industrial Average ( ^DJI) trading up 30 points (0.2%) at 17,107 as of Tuesday, Aug. 26, 2014, 4:20 PM ET. The NYSE advances/declines ratio sits at 2,006 issues advancing vs. 1,020 declining with 179 unchanged. The Health Care sector as a whole closed the day up 1.1% versus the S&P 500, which was up 0.1%. Top gainers within the Health Care sector included VirtualScopics ( VSCP), up 2.5%, Oragenics ( OGEN), up 3.0%, Semler Scientific ( SMLR), up 3.9%, Daxor ( DXR), up 4.6% and Cellectar Biosciences ( CLRB), up 2.0%. TheStreet Ratings Group would like to highlight 3 stocks pushing the sector higher today: Daxor ( DXR) is one of the companies that pushed the Health Care sector higher today. Daxor was up $0.31 (4.6%) to $7.08 on light volume. Throughout the day, 800 shares of Daxor exchanged hands as compared to its average daily volume of 5,400 shares. The stock ranged in a price between $7.01-$7.18 after having opened the day at $7.18 as compared to the previous trading day's close of $6.77. Daxor Corporation, a medical device manufacturing company, offers biotech services in the United States. The company develops and markets BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume. Daxor has a market cap of $28.5 million and is part of the drugs industry. Shares are down 0.9% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Daxor a buy, no analysts rate it a sell, and none rate it a hold. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings rates Daxor as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Highlights from TheStreet Ratings analysis on DXR go as follows: